Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Cellceutix Corporation
- Target Recruit Count
- 115
- Registration Number
- NCT02494479
- Locations
- 🇺🇸
Cellceutix Study Center, Las Vegas, Nevada, United States
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
- Conditions
- HIVAcute HIV Infection
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT02384395
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Duke University Health System, Durham, North Carolina, United States
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182765
Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Cellceutix Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT02101216
- Locations
- 🇺🇸
Phase One Solutions Inc., Miami Gardens, Florida, United States
Tenofovir Abacavir Platelet Activation Study
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Jan Gerstoft
- Target Recruit Count
- 43
- Registration Number
- NCT02093585
- Locations
- 🇩🇰
Rigshospitalet, Klinik for Infektionsmedicin og Reumatologi, 8622, Copenhagen Ø, Copenhagen, Denmark
Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- PENTA Foundation
- Target Recruit Count
- 19
- Registration Number
- NCT01982396
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
🇬🇧St. Mary's Hospital, London, United Kingdom
Determining the Effect of Abacavir on Platelet Activation
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 23
- Registration Number
- NCT01886638
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
Abacavir and Lamivudine PK in Children
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2016-02-22
- Target Recruit Count
- 30
- Registration Number
- NCT01656122
- Locations
- 🇹🇭
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
Evaluation of the Bioequivalence of a Combined Formulated Tablet
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 66
- Registration Number
- NCT01622790
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
- Conditions
- Healthy SubjectsInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT01366547
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.